Literature DB >> 8310796

Tumor induction by ras and myc oncogenes in fetal and neonatal brain: modulating effects of developmental stage and retroviral dose.

H Radner1, Y el-Shabrawi, R H Eibl, O Brüstle, L Kenner, P Kleihues, O D Wiestler.   

Abstract

Introduction into fetal rat brain cells of a replication-defective retroviral vector harboring v-Ha-ras and v-gag-myc rapidly causes the induction of highly malignant undifferentiated neuroectodermal tumors following transplantation into the brains of syngeneic hosts [Wiestler, et al. (1992) Cancer Res. 52: 3760-3767]. In the present study, we have investigated the modulating effect of the developmental stage of neural target cells and of the dose of the retroviral vector used in the grafting experiments. Exposure of fetal cells from embryonic day (E)12 or E14 produced a 100% incidence of malignant neuroectodermal tumors which led to the death of recipient animals after a median latency period of 32 days. A 100-fold reduction of the virus dose from 2.062 x 10(6) to 2.062 x 10(4) focus-forming units/ml resulted in a lower tumor incidence of 25%. Of six neural grafts exposed to v-Ha-ras and v-myc at E16, only one showed evidence of tumorigenesis (low-grade astrocytoma and hemangioma). All other transplants were morphologically normal for observation periods of 26 weeks, indicating a marked loss of transforming activity of ras and myc in more advanced stages of brain development. In retrovirus-exposed donor cells which caused the development of neural tumors in recipient rats, malignant transformation was also evident during culture in vitro, usually after 9-12 days. Oncogene complementation was also studied in the newborn rat brain. After microinjection of the retroviral vector into the brain at postnatal day (P)0, P1 and P3, 5 out of 20 animals (25%) developed a total of seven brain tumors. Histopathologically, three of these neoplasms were malignant neuroectodermal tumors which, in contrast to those induced in fetal brain transplants showed evidence of focal glial and/or neuronal differentiation. In addition, we observed one oligodendroglioma, two hemangiomas and a malignant hemangioendothelioma. These data indicate that neural precursor cells and endothelia of the rat brain represent the major target cells for the complementary action of ras and myc and that the use of target cells from later developmental stages (E16 and postnatal) leads to the induction of both primitive and more differentiated neoplasms.

Entities:  

Mesh:

Year:  1993        PMID: 8310796     DOI: 10.1007/bf00228580

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  14 in total

1.  The natural history of cancer.

Authors:  L FOULDS
Journal:  J Chronic Dis       Date:  1958-07

2.  Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ.

Authors:  T C Thompson; J Southgate; G Kitchener; H Land
Journal:  Cell       Date:  1989-03-24       Impact factor: 41.582

3.  Construction and applications of a highly transmissible murine retrovirus shuttle vector.

Authors:  C L Cepko; B E Roberts; R C Mulligan
Journal:  Cell       Date:  1984-07       Impact factor: 41.582

Review 4.  The sequential analysis of cancer development.

Authors:  E Farber; R Cameron
Journal:  Adv Cancer Res       Date:  1980       Impact factor: 6.242

5.  Selective induction by N-nitrosoethylurea of oligodendrogliomas in fetal forebrain transplants.

Authors:  P C Burger; T Shibata; A Aguzzi; P Kleihues
Journal:  Cancer Res       Date:  1988-05-15       Impact factor: 12.701

6.  Activation of Ki-ras gene by point mutation in human liver angiosarcoma associated with vinyl chloride exposure.

Authors:  M J Marion; O Froment; C Trépo
Journal:  Mol Carcinog       Date:  1991       Impact factor: 4.784

Review 7.  Retrovirus-mediated oncogene transfer into neural transplants.

Authors:  O D Wiestler; O Brüstle; R H Eibl; H Radner; A Aguzzi; P Kleihues
Journal:  Brain Pathol       Date:  1992-01       Impact factor: 6.508

8.  Oncogene complementation in fetal brain transplants.

Authors:  O D Wiestler; A Aguzzi; M Schneemann; R Eibl; A von Deimling; P Kleihues
Journal:  Cancer Res       Date:  1992-07-01       Impact factor: 12.701

9.  The ras and myc oncogenes cooperate in tumor induction in many tissues when introduced into midgestation mouse embryos by retroviral vectors.

Authors:  S J Compere; P Baldacci; A H Sharpe; T Thompson; H Land; R Jaenisch
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

10.  Cell type-specific tumor induction in neural transplants by retrovirus-mediated oncogene transfer.

Authors:  A Aguzzi; P Kleihues; K Heckl; O D Wiestler
Journal:  Oncogene       Date:  1991-01       Impact factor: 9.867

View more
  7 in total

1.  EGFR signals downregulate tumor suppressors miR-143 and miR-145 in Western diet-promoted murine colon cancer: role of G1 regulators.

Authors:  Hongyan Zhu; Urszula Dougherty; Victoria Robinson; Reba Mustafi; Joel Pekow; Sonia Kupfer; Yan Chun Li; John Hart; Kathleen Goss; Alessandro Fichera; Loren Joseph; Marc Bissonnette
Journal:  Mol Cancer Res       Date:  2011-06-08       Impact factor: 5.852

2.  Association between regulator of telomere elongation helicase 1 polymorphism and susceptibility to glioma.

Authors:  Shujun Pei; Feng Zhao; Junle Liu; Qiang Fu; Peizhong Shang
Journal:  Int J Clin Exp Med       Date:  2015-01-15

3.  Long non-coding RNA GASL1 may inhibit the proliferation of glioma cells by inactivating the TGF-β signaling pathway.

Authors:  Yuhua Hu; Baohua Jiao; Lingyou Chen; Man Wang; Xinwang Han
Journal:  Oncol Lett       Date:  2019-04-18       Impact factor: 2.967

Review 4.  Testing electromagnetic fields for potential carcinogenic activity: a critical review of animal models.

Authors:  J McCann; R Kavet; C N Rafferty
Journal:  Environ Health Perspect       Date:  1997-02       Impact factor: 9.031

5.  IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced.

Authors:  Huixia Zhu; Ye Zhang; Jianfeng Chen; Jiangdong Qiu; Keting Huang; Mindan Wu; Chunlin Xia
Journal:  PLoS One       Date:  2017-01-04       Impact factor: 3.240

6.  LINK-A lncRNA participates in the pathogenesis of glioma by interacting with survivin.

Authors:  Xia Hua; Guangxing Li; Zhongtao Liu; Zhanfeng Niu
Journal:  Exp Ther Med       Date:  2019-07-01       Impact factor: 2.447

7.  Sevoflurane inhibits cell proliferation and migration of glioma by targeting the miR‑27b/VEGF axis.

Authors:  Xi Zhan; Changcheng Lei; Linzhu Yang
Journal:  Mol Med Rep       Date:  2021-03-31       Impact factor: 2.952

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.